Patents by Inventor Guozhang Xu

Guozhang Xu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-ones as factor XIa inhibitors
    Patent number: 11958856
    Abstract: A compound of formula (I) or a pharmaceutically acceptable salt or stereoisomer thereof: Pharmaceutical compositions containing said compounds, and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: July 21, 2022
    Date of Patent: April 16, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Zhijie Liu
  • Substituted pyridine N-oxide derivatives useful as a factor XIa inhibitors
    Patent number: 11919881
    Abstract: The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: March 5, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Tho V. Thieu, Zhijie Liu, Micheal D. Gaul
  • Cereblon Ligands and Uses Thereof
    Publication number: 20240059704
    Abstract: Described herein are compounds or conjugates of of Formulae II and I and their pharmaceutically acceptable salts, solvates, or stereoisomers, as well as their uses (e.g., as cereblon-binding agents or bifunctional degraders for degrading certain proteins).
    Type: Application
    Filed: July 12, 2023
    Publication date: February 22, 2024
    Inventors: Shaomeng Wang, Zhixiang Chen, Dimin Wu, Ranjan Kumar Acharyya, Weiguo Xiang, Rohan Rej, Longchuan Bai, Xuqing Zhang, Guozhang Xu
  • 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives useful as a factor XIa inhibitors
    Patent number: 11897880
    Abstract: The present invention is directed to 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: April 29, 2022
    Date of Patent: February 13, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Tianbao Lu, Zhijie Liu, Micheal D. Gaul
  • Bicyclic pyridine N-oxide derivatives useful as a factor XIa inhibitors
    Patent number: 11845748
    Abstract: The present invention is directed to bicyclic pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: December 19, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Zhijie Liu, Micheal D. Gaul
  • Pyridine N-oxide derivatives useful as factor XIa inhibitors
    Patent number: 11814364
    Abstract: The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Grant
    Filed: March 17, 2022
    Date of Patent: November 14, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Guozhang Xu, Boying Guo, Zhijie Liu, Jing Zhang, Micheal D. Gaul, Eugene B. Grant, Mark J. Macielag, Tianbao Lu, Tho V. Thieu
  • COMPOUNDS USEFUL AS FACTOR XIA INHIBITORS
    Publication number: 20230312560
    Abstract: The present invention is directed to Factor XIa inhibitors, tautomers, stereoisomers, isotopologues, and pharmaceutically acceptable salts and solvates thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders, and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2021
    Publication date: October 5, 2023
    Inventors: Guozhang XU, Mark J. MACIELAG, Zhijie LIU, Tho V. THIEU, Ravi NARGUND
  • 3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
    Publication number: 20230295157
    Abstract: The present invention is directed to 3-(1H-imidazol-2-yl)-2,3,8,8a-tetrahydroindolizin-5(1H)-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 22, 2021
    Publication date: September 21, 2023
    Inventors: Guozhang XU, Micheal D. GAUL, Tho V. THIEU, Jing ZHANG, Mark WALL, Ling Hua GAO, Bin ZHU, Tianbao LU, Boying GUO, Zhijie LIU, Ravi NARGUND, Mark J. MACIELAG
  • Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
    Publication number: 20230183233
    Abstract: The present invention is directed to bicyclic pyridinon-2-one and pyrimidin-4-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2022
    Publication date: June 15, 2023
    Inventors: Guozhang Xu, Mark J. Macielag, Micheal D. Gaul, Zhijie Liu
  • Bicyclic Pyridin-2-one and pyrimidin-4-one Derivatives Useful As a Factor XIa Inhibitors
    Publication number: 20230097157
    Abstract: The present invention is directed to bicyclic pyridinon-2-one and pyrimidin-4-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2022
    Publication date: March 30, 2023
    Inventors: Guozhang Xu, Mark J. Macielag, Micheal D. Gaul, Tho V. Thieu, Zhijie Liu
  • PYRIDINE N-OXIDE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
    Publication number: 20230091768
    Abstract: The present invention is directed to pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: March 23, 2023
    Inventors: Guozhang Xu, Boying Guo, Zhijie Liu, Jing Zhang, Micheal D. Gaul, Eugene B. Grant, Mark J. Macielag, Tianbao Lu, Tho V. Thieu
  • 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-one Derivatives Useful As Factor XIa Inhibitors
    Publication number: 20230067355
    Abstract: The present invention is directed to 1,2,3,8,9,9a-hexahydro-5H-pyrrolo[1,2-a]azepin-5-one derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2022
    Publication date: March 2, 2023
    Inventors: Guozhang Xu, Zhijie Liu
  • 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide Derivatives Useful As a Factor XIa Inhibitors
    Publication number: 20230064443
    Abstract: The present invention is directed to 5-oxo-1,2,3,5,8,8a-hexahydroindolizine-3-carboxamide derivatives, stereoisomers, isotopologues, and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: July 21, 2022
    Publication date: March 2, 2023
    Inventors: Guozhang Xu, Mark J. Macielag
  • 7,8-DIHYDROBENZO[E]PYRIDO[3,4-C]AZOCINE-2,5(3H,6H)-DIONE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS
    Publication number: 20220389005
    Abstract: The present invention is directed to 7,8-dihydrobenzo[e]pyrido[3,4-c]azocine-2,5(3H,6H)-dione derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: April 29, 2022
    Publication date: December 8, 2022
    Inventors: Guozhang Xu, Tianbao Lu, Zhijie Liu, Micheal D. Gaul
  • SUBSTITUTED PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS
    Publication number: 20220315561
    Abstract: The present invention provides imidazole substituted pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: October 6, 2022
    Inventors: Guozhang Xu, Tho V. Thieu, Zhijie Liu, Micheal D. Gaul
  • BICYCLIC PYRIDINE N-OXIDE DERIVATIVES USEFUL AS A FACTOR XIA INHIBITORS
    Publication number: 20220306632
    Abstract: The present invention is directed to bicyclic pyridine N-oxide derivatives, stereoisomers, isotopologues, isotopomers and pharmaceutically acceptable salts thereof, pharmaceutical compositions containing said compounds and the use of said compounds in the treatment and/or prophylaxis of thromboembolic disorders, inflammatory disorders and diseases or conditions in which plasma kallikrein activity is implicated.
    Type: Application
    Filed: March 17, 2022
    Publication date: September 29, 2022
    Inventors: Guozhang Xu, Zhijie Liu, Micheal D. Gaul
  • QUINAZOLIN-4-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS
    Publication number: 20220267298
    Abstract: The present invention is directed to quinazolin-4-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including the treatment of for example, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, End-stage kidney disease, kidney failure, etc.
    Type: Application
    Filed: July 29, 2020
    Publication date: August 25, 2022
    Inventors: Guozhang Xu, Micheal D. Gaul
  • PHTHALAZIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS
    Publication number: 20220242850
    Abstract: The present invention is directed to phthalazin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including the treatment of for example, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, End-stage kidney disease, kidney failure, etc.
    Type: Application
    Filed: June 29, 2020
    Publication date: August 4, 2022
    Inventors: Guozhang Xu, Micheal D. Gaul
  • FUSED ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS
    Publication number: 20220220125
    Abstract: The present invention is directed to fused isoindolin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2.
    Type: Application
    Filed: April 15, 2020
    Publication date: July 14, 2022
    Inventor: Guozhang Xu
  • ISOINDOLIN-1-ONE DERIVATIVES USEFUL AS GRK2 INHIBITORS
    Publication number: 20220009906
    Abstract: The present invention is directed to isoindolin-1-one derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by GRK2, including, but not limited to, cardiac failure, cardiac hypertrophy, hypertension, Type II diabetes Mellitus, NASH, NAFLD, end stage chronic kidney disease, kidney failure, etc.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 13, 2022
    Inventors: Guozhang Xu, Eugene B. Grant, Gee-Hong Kuo, Micheal D. Gaul